Growing Adoption of Gene Therapy Platforms, Expanding Agricultural Biotechnology Applications, and Accelerating Clinical Trial Activity Drive Robust Market Expansion.Austin, United States, Feb. 27, ...
Two studies published in Nature Medicine June 11 contribute to a small body of literature suggesting cells edited with CRISPR-Cas9 may cause cancer. Here are five things to know about the studies and ...
Gene editing has enormous potential to help feed the world’s growing population, but it’s currently difficult, time-consuming ...
Hosted on MSN
CRISPR and the Ethics of Human Germline Intervention
Genetic modifications in reproductive cells, such as eggs, sperm, or embryos, are commonly referred to as germline editing and are heritable. 1 CRISPR-Cas 9, which stands for clustered regularly ...
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
CRSP’s main value driver is Casgevy, which was approved for sickle cell disease and β-thalassemia. It’s a one-time ex vivo CRISPR/Cas9 stem‐cell therapy. Unfortunately, Casgevy’s rollout has been slow ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results